Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

ENTA : 11.47 (-1.55%)
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday

The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.

JEF : 60.96 (+0.21%)
ABBV : 193.26 (-0.10%)
ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced topline data from SPRINT ( S ARS-Cov-2...

ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal second...

ENTA : 11.47 (-1.55%)
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial...

ENTA : 11.47 (-1.55%)

Barchart Exclusives

Dividend Aristocrats: The Best of the Best for Stable Income
Dividend Aristocrats' ability to increase their dividends indicates strong earnings and a solid business foundation, which lowers investment risk. Moreover, their consistent earnings growth often enables them to outperform broader market indices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar